Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 10,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 10,000 shares of Akero Therapeutics stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $28.03, for a total transaction of $280,300.00. Following the completion of the sale, the chief operating officer now directly owns 218,083 shares of the company's stock, valued at approximately $6,112,866.49. The trade was a 4.38 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Jonathan Young also recently made the following trade(s):

• On Tuesday, December 10th, Jonathan Young sold 2,503 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total transaction of $77,067.37.
• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.13, for a total transaction of $321,300.00.
• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.57, for a total transaction of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.15, for a total transaction of $1,206,000.00.

Akero Therapeutics Stock Performance

Shares of NASDAQ:AKRO traded down $0.60 on Monday, hitting $27.64. 648,338 shares of the company were exchanged, compared to its average volume of 829,566. The company's 50 day moving average price is $30.49 and its two-hundred day moving average price is $27.95. Akero Therapeutics, Inc. has a one year low of $15.32 and a one year high of $37.00. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of -7.37 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Research analysts expect that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current year.

Analyst Ratings Changes

AKRO has been the subject of a number of research analyst reports. Citigroup initiated coverage on shares of Akero Therapeutics in a research report on Monday, November 18th. They set a "buy" rating and a $65.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Akero Therapeutics in a research report on Monday, November 18th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $46.83.

Institutional Trading of Akero Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Exome Asset Management LLC bought a new stake in Akero Therapeutics in the third quarter valued at about $2,212,000. Barclays PLC increased its stake in Akero Therapeutics by 127.9% in the third quarter. Barclays PLC now owns 127,668 shares of the company's stock valued at $3,662,000 after acquiring an additional 71,652 shares during the period. Y Intercept Hong Kong Ltd increased its stake in Akero Therapeutics by 13.8% in the third quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company's stock valued at $485,000 after acquiring an additional 2,049 shares during the period. XTX Topco Ltd bought a new stake in Akero Therapeutics in the third quarter valued at about $308,000. Finally, Wellington Management Group LLP increased its stake in Akero Therapeutics by 54.4% in the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company's stock valued at $226,554,000 after acquiring an additional 2,782,029 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.